Introduction
Hepatocellular carcinoma (HCC) is a solid tumor associated with high mortality rate, due to the limited treatment options available against this disease. According to the statistics provided by the American Cancer Society, the 5-year survival rate between 2001 and 2007 for all liver cancers is only 14 % [1] . The prognosis is even more unfavorable (4 % 5-year survival rate) when the cancer spreads to distant sites [2] .
Alteration of metabolism, including elevated glycolysis and de novo lipogenesis is one of the hallmarks of cancer. Fatty acid synthase (FASN) catalyzes the final step in the conversion of carbohydrates to palmitate, and is therefore essential for mammalian lipogenesis. Although one might expect tumors to be able to take up dietary fat, virtually all solid tumors of epithelial origin require FASN for survival and proliferation [3] [4] [5] [6] [7] [8] [9] . Increased expression of FASN is a hallmark of all major epithelial cancers (for review see [10] ) and is usually associated with poor prognosis [4, 5, [11] [12] [13] [14] . A blockade of FASN by siRNA-mediated knockdown or covalent inhibitors arrests the tumor cell cycle at G1/S and causes tumor cell apoptosis [9, [15] [16] [17] [18] [19] . Another study suggests that upregulation of FASN may even be oncogenic [20] . Recent studies show a strong link between lipogenesis, FASN, and HCC [21] [22] [23] [24] [25] [26] [27] . A previous report from our group demonstrated that de novo lipogenesis and FASN levels increase as hepatocytes progress from non-tumorigenic to HCC [22] . This change in lipogenic phenotype correlates with activation of AKT/mTOR/RSP6 signaling cascades in human HCC [22] .
The aberrant metabolic program of tumor cells has led to the development of metabolic imaging systems. For instance, the finding of increased glucose utilization by cancer cells has been successfully used to develop the 2-deoxy-2-[ 18 
Materials and Methods

Constructs and Reagents
The constructs used for mouse injection, including pT3-EF1α-myrAKT, pT2-Caggs-NRasV12, pT3-EF1α-c-Met, and pCMV/ sleeping beauty transposase (pCMV/SB), were described previously [43, 44] . Human PIK3CA with H1047R mutation (Addgene plasmid 12524) was cloned into pT3-EF1α vector via the Gateway PCR cloning strategy (Invitrogen, Carlsbad, CA). All plasmids were purified using the Endotoxin-free Maxi prep kit (Sigma, St. Louis, MO) before being injected into the mice.
2 H 2 O was purchased from Sigma. The [ 11 C]acetate was synthesized by trapping the 11 CO 2 in a methyl magnesium bromide solution and then distillation into saline [45] at the radiochemistry/ radiopharmacy facility at the University of California, San Francisco (UCSF). Radiosynthesis and quality control processes followed standard procedures established at the facility.
Hydrodynamic Injection and Mouse Monitoring
Wild-type FVB/N mice were obtained from Charles River (Wilmington, MA). Hydrodynamic injection was performed as described [46] . In brief, 10 μg pT3-EF1α-myrAKT and 10 μg pT2-Caggs-NRasV12 were mixed with pCMV/SB in a ratio of 25:1. Similarly, 10 μg pT3-EF1α-c-Met and 10 μg pT3-EF1α-PIK3CAH104R were mixed with pCMV/SB. The plasmid mixture was diluted in 2 ml saline (0.9 % NaCl), filtered through 0.22-μm filter, and injected into the lateral tail vein of 6 to 8-week-old FVB/ N mice in 5 to 7 s. Mice were monitored two times per week for liver tumor development as palpable abdominal mass. All mouse procedures, including housing, feeding, and monitoring were performed based on the protocol approved by the UCSF Institutional Animal Care and Use Committee.
Immunohistochemical Staining
Upon euthanasia, mouse liver tissues were collected and fixed in 4 % paraformaldehyde (PFA) overnight at 4°C and embedded in paraffin. For antigen retrieval, slides were put into 10-mM sodium citrate buffer (pH 6.0), and placed in a microwave on high for 10 min. Slides were blocked with 5 % goat serum and the AvidinBiotin blocking kit (Vector Laboratories, Burlingame, CA). Primary antibodies were added to the slides and incubated overnight at 4°C. Slides were washed and incubated with a biotin-conjugated secondary antibody. Detection was performed with the ABC-Elite peroxidase kit (Vector Laboratories) using the DAB as the substrate. Primary antibodies used in the study include: Anti-FASN and anti-acetyl-CoA carboxylase (anti-ACC) antibodies; both were obtained from Cell Signaling Technology Inc.
Oil Red O Staining
The Oil Red O stain kit (American MasterTech) was used for the Oil Red O staining, following the instruction provided by the manufacturer.
Lipid Analysis
Lipid analysis was performed by the Vanderbilt University MMPC/ DRTC Lipid Core as described in our previous publication [47] .
Measurement of de novo Lipogenesis Rate in Mouse Liver Tumor Samples
Wild-type FVB/N mice or tumor-bearing mice (with palpable abdominal mass) were injected with a single bolus dose of 2 H 2 O to achieve target total body water enrichment of 4.0 % 2 H-water. The amount of 2 H 2 O was estimated based on total body weight of which about 70 % is approximately body water. This value was then multiplied by 4 % to yield the amount of heavy water to be injected as a single bolus (thus, a 30-g mouse would receive 0.84 ml of heavy water). Mice were euthanized 8 h after D 2 0 injection. Blood was collected and liver tissues were snap frozen in liquid nitrogen.
In vivo de novo lipogenesis was measured using the deuterium oxide ( 2 H 2 O) water method [48] [49] [50] ]×100, where n is the number of exchangeable hydrogens, which is assumed to 22 [48, 49] . 2 H Labeling of Body Water-2 H-labeled total body water enrichment was measured from the blood collected from each mouse and determined using the acetone exchange where the 2 H-label in acetone, as measured by GC-MS, reflects the enrichment of total body water [50] .
Animal Imaging Protocol
All in vivo animal imaging was performed using a microPET/CT scanner (Inveon dedicated PET (DPET) docked with CT in the multimodality (MM) platform, Siemens Medical Solutions USA, Inc., Malvern, PA). Murine PET/CT imaging followed established standard operating procedures approved by the UCSF Institutional Animal Care and Use Committee (IACUC) and Laboratory Animal Resource Center (LARC).
Tumor imaging using [ 11 C]acetate was performed when the liver tumors were palpable, meaning substantial growth was apparent. After the in vivo imaging sessions and the radionuclides decayed to background, the animals were euthanized and the presence of liver tumors was confirmed by visual investigation. For all animal procedures, a custom-made mouse tail vein catheter consisting of a 28-gauge needle and a 100-150-mm-long polyethylene microtubing (PE/1, Scientific Commodities, Inc., Lake Havasu City, AZ) was placed through the tail vein to ensure intravenous administration of radiotracers. The absence of leakage and misinjection was verified for all microPET/CT scans by wholebody inspection of reconstructed PET images. Animals were maintained under 1-2 % isoflurane anesthesia during radiotracer administration and imaging sessions. All animals were also fasted overnight before the day of each imaging session.
For the [ 11 C]acetate imaging, 6.81-15.54 MBq was administered to five AKT/Ras and three PI3K/Met mice intravenously, immediately followed by 30 min of dynamic multiframe PET data acquisitions. The catheter was placed before the animals were transported to the microPET/CT scanner, and before the [ 11 C]acetate administration, the catheter placement within the vein was confirmed by flushing a small amount of saline. The same dynamic PET imaging protocol was applied to an additional six FVB/N normal mice for control measurements of the influx rate constant measurements of acetate metabolism.
[ 11 C]acetate PET data were reconstructed using a threedimensional ordered-subsets expectation maximization (3D OS-EM) with maximum a posteriori (MAP) algorithm provided by the manufacturer. CT-based attenuation correction was incorporated in PET reconstruction algorithms. Dynamic PET data were reconstructed into dynamic multiframes (5 s×6, 10 s×6, 30 s×3, 60 s×7, 600 s×2) using the same reconstruction algorithm. The scan parameters for in vivo microCT were 120 projections of continuous rotations to cover 220°with an x-ray tube operated at 80 kVp, 0.5 mA, and 175 ms exposure time. The CT data were reconstructed using a modified cone-beam Feldkamp reconstruction algorithm (COBRA, Exxim Computing Corporation, Pleasanton, CA We used a commercially available software package (Inveon Research Workplace 2.0, Siemens Medical Solutions USA, Inc., Malvern, PA) for all analyses included in this manuscript. For the kinetic modeling of [ 11 C]acetate data, the blood input function was also derived from the left ventricular myocardial blood pool in reconstructed PET images. We used a small volume of interest, typically encompassing 2-3 voxels, well within the left ventricular chamber for the input function derivation in order to minimize partial volume effect from the myocardial uptake of [ 11 C]acetate as well as the spill-over effect of the blood pool uptake. No other partial volume error compensation technique was used.
Statistical Analysis
All data were analyzed with Prism 6 (GraphPad, San Diego, CA). Comparisons were performed with two-tailed unpaired t test or Newman-Keuls multiple comparison test.
Results
Increased de novo Lipogenesis in AKT/Ras-and PI3K/Met-Induced Liver Tumors
In our recent studies, we demonstrated that in humans, de novo lipogenesis and FASN increase as hepatocytes progress from non-tumorigenic to full malignancy [22] . This change in lipogenic phenotype correlates with activation of the AKT/mTOR/RSP6 signaling cascade [22] . Furthermore, our studies suggested coordinated activation of AKT/ mTOR and Ras/MAPK pathways in the subset of human HCCs with aggressive phenotypes [53] . To study the biochemical crosstalk between the two pathways, we developed a murine liver tumor model with activated AKT/mTOR and Ras/MAPK pathways via hydrodynamically co-transfecting myrAKT and NRasV12 protooncogenes (hereinafter, AKT/Ras) [43] . AKT/Rasinjected mice developed lethal burden of liver tumors by 5 to 6 weeks postinjection. Histologically, tumors are comprised of poorly differentiated HCC with small percentage of cholangiocarcinoma (CCA) or mixed HCC/CCA (Fig. 1a) . Tumor cells showed concomitant activation of the AKT/mTOR and Ras/MAPK cascades [43] .
Activating mutations of PIK3CA are found in approximately 4 % of human HCC samples (COSMIC database); among them, PIK3CAH1047R is one of the most common PIK3CA mutations. Overexpression and activation of c-Met is one of the most frequently observed biochemical events in HCC [54] . Thus, we developed another murine HCC model by hydrodynamically co-transfecting PIK3CAH1047R and c-Met (hereinafter PI3K/Met). PI3K/Met co-expression induced HCC formation by~15 weeks postinjection (Fig. 1a) . The detailed description of this murine HCC model will be presented in a separated manuscript (Wang C, manuscript in preparation). Importantly, PI3K/Met liver tumors showed elevated AKT and Ras pathway activation (data not shown). Therefore, these mice provide another useful murine HCC model to study the molecular events associated with activation of AKT/mTOR and Ras/MAPK cascades in hepatocarcinogenesis.
As both AKT/Ras and PI3K/Met liver tumors have high levels of the AKT/mTOR pathway, we investigated whether the lipogenic pathway is activated in these murine liver tumor models. Indeed, we found large lipid droplet accumulation in tumor cells in both mouse models (Fig. 1b) . Consistently, AKT/Ras and PI3K/Met tumor cells showed high levels of total triglycerides (TG) and cholesterol esters (CE) compared to normal liver tissues (Fig. 2) . To confirm that the accumulation of lipid droplets in tumors is the result of increased rate of lipogenesis, we used heavy water ( 2 H 2 O) as the stable isotope tracer [48, 50] . The results demonstrated significantly increased de novo lipogenesis rate in AKT/Ras and PI3K/Met liver tumors in comparison with normal liver tissues (Fig. 3) . Consistent with this, the expression of lipogenic pathway genes, including FASN and ACC, was significantly increased in AKT/Ras and PI3K/Met tumors (Fig. 1c, d) .
In summary, our data demonstrate that liver tumors induced by AKT/Ras and PI3K/Met overexpression, both exhibiting the activation of the AKT/mTOR signaling, have an increased de novo lipogenesis rate and a profound lipid accumulation in tumor cells. Thus, these tumor models (Fig. 4a) .
The K i values measured from dynamic [
11 C]acetate PET/ CT imaging (Fig. 4b) In summary, our study shows that despite the increased FASN expression and de novo lipogenesis rate in PI3K/Met mouse liver tumors, no significantly increased [ 11 C]acetate PET signal can be detected in these mice. ]FDG can potentially serve not only for tumor detection but also as an indicator of the increased activity of a specific metabolic process. If the detected process is demonstrated to be required for a tumor cell proliferation and/or viability, PET imaging could then allow to stratify patients for appropriate metabolism-based therapies. However, in order to achieve this goal further, thorough evaluation of mechanisms underlying increased PET signals in various tumors is required.
Having said that the complementary metabolic imaging probes are essential to further understand the specific tumor biology in malignant tumors such as HCC, the main subject of this manuscript, it is also interesting to see how [ 18 F]FDG's case in studying glucose utilization and metabolism of cancers is compared to hyperpolarized [ 13 C]pyruvate magnetic resonance spectroscopic imaging [59] .
Finally, a therapeutic target based on the biochemical evidence of oncogenic pathway inhibition can be better understood and targeted if we can stratify the potential responders from nonresponders. For this purpose, the imaging probe that is linked to specific molecular pathways will be potentially critical in the management of cancers using a molecularly based treatment strategy [60] .
Conclusion
Using mouse models of HCCs induced by AKT/Ras and PI3K/Met proto-oncogenes, we have evaluated the correlation between de novo lipogenesis (including the expression of the enzymes involved in de novo lipogenesis, FASN, and ACC) and the intensity of in vivo [
11 C]acetate PET signal. The data obtained from our investigation demonstrate that increased in vivo [
11 C]acetate PET signal does not always correlate with increased lipid biogenesis in HCCs. 
